Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Functional analysis of cyclin D2 and p27Kip1 in cyclin D2 transgenic mouse mammary gland during development

Abstract

Two mammary gland phenotypes were detected in pregnant MMTV-cyclin D2 transgenic mice; line D2–53 exhibited a lack of alveologenesis and failure to nurse, whereas line D2–58 featured a reduction in alveologenesis, but retained normal nursing behavior. In pregnant mammary glands, cyclin D2 protein levels were twofold (P<0.107) and 3.8-fold (P<0.0076) higher in line D2–58 and D2–53, respectively, compared to wild type. Concomitantly with the increase in cyclin D2 was a fivefold decrease in cyclin D1 hyper-phosphorylated isoform in mammary glands of pregnant cyclin D2–58 mice. Because cyclin D1 is a critical molecule in normal mammary lobuloalveolar development, these data suggest that overexpression of cyclin D2 may block mammary lobuloalveolar development through inhibition of cyclin D1 phosphorylation. During mammary gland development, p27kip1 protein level oscillated in a similar profile in wild type and cyclin D2 transgenic mice, but was consistently higher in the cyclin D2 mice suggesting that p27kip1 functions downstream of cyclin D2. The ratio of p27kip1-cdk4/p27kip1-cdk2 was 6.5-fold (P<0.0003) higher in cyclin D2 mammary glands compared to wild type in pregnant animals. This ratio reversed to 2.2-fold (P<0.005) higher in wild type compared to cyclin D2 mammary glands in involution suggesting that overexpression of cyclin D2 moderately induced apoptosis during pregnancy but accelerated involution. Collectively, the effects of cyclin D2 overexpression on mammary gland development during pregnancy and involution are attributed to two major factors, altered p27kip1 protein level and inhibition of cyclin D1 phosphorylation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Barnes DM, Gillett CE . 1998 Breast Cancer Res. Treat. 52: 1–15

  • Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J . 1994 Int. J. Cancer 57: 353–361

  • Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorage W, Reed S, Sicinski P, Bartek J, Elers M . 1999 EMBO J 18: 5321–5333

  • Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RL . 1993 Oncogene 8: 2127–2133

  • Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D, Peters G . 1995 Cancer Lett. 90: 43–50

  • Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S . 2001 Cancer Res. 61: 2782–2787

  • Fantl V, Edwards PAW, Steel JH, Vonderhaar BK, Dickson C . 1999 Dev. Biol. 212: 1–11

  • Fantl V, Stamp G, Andrew A, Rosewell I, Dickson C . 1995 Genes Dev. 9: 2364–2372

  • Han EK, Begemann M, Sgambato A, Soh JW, Doki Y, Xing WQ, Liu W, Weinstein IB . 1996 Cell Growth Differ. 7: 699–710

  • Han EK, Sgambato A, Jiang W, Zhang YJ, Santella RM, Doki Y, Cacace AM, Schieren I, Weinstein IB . 1995 Oncogene 10: 953–961

  • Harvey JM, Clark GM, Osborne CK, Allred DC . 1999 J. Clin. Oncol. 17: 1474–1481

  • Hartwell LH, Weinert TA . 1989 Science 246: 629–634

  • Houldsworth J, Reuter V, Bosl G, Chaganti R . 1997 Cell Growth Differ. 8: 292–299

  • Hunter T, Pines J . 1994 Cell 79: 573–582

  • Janz S, Jones GM, Muller JR, Potter M . 1995 Curr. Top Microbiol. Immunol. 194: 373–380

  • Jiang W, Kahn SM, Zhou P, Zhang YJ, Cacace AM, Infante AS, Doi S, Santella RM, Weinstein IB . 1993 Oncogene 8: 3447–3457

  • Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A, Peters G . 1991 Oncogene 6: 439–444

  • Lukas J, Bartkova J, Welcker M, Petersen OW, Peters G, Strauss M, Bartek J . 1995 Oncogene 10: 2125–2134

  • Meyyappan M, Wong H, Hull C, Riabowol KT . 1998 Mol. Cell. Biol. 18: 3163–3172

  • Motpokura T, Bloom T, Goo-Kim H, Jüppner H, Ruderman JV, Kronenberg HM, Arnold A . 1991 Nature 350: 512–515

  • Murray AW . 1992 Nature 349: 603–608

  • Nivins JR . 1992 Science 258: 424–429

  • O'Connell MJ, Nurse P . 1994 Curr. Opin. Cell. Biol. 6: 867–871

  • Oyama T, Kashiwabara K, Yoshimoto K, Arnold A, Koerner F . 1998 Cancer Res. 58: 2876–2880

  • Pagano M, Theodoras AM, Tam SW, Draetta GF . 1994 Genes Dev. 8: 1627–1639

  • Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege MS, Brielmeier M, Ellwart J, Kohlhuber F, Bornkamm GW, Polack A, Eick D . 2000 Int. J. Cancer 87: 787–793

  • Perez-Roger I, Kim S-H, Griffiths B, Sewing A, Land H . 1999 EMBO J 18: 5310–5320

  • Pestka S, Langer JA, Zoon KC, Samuel CE . 1987 Annu. Rev. Biochem. 56: 727–777

  • Rasmussen SB, Young LJT, Smith GH . 2000 Methods in mammary gland biology and breast cancer Ip MM and Asch BB (ed) New York: Kluwer Academic/Plenum Publishers, USA pp 75–85

  • Ravanko K, Jarvinen K, Paasinen-Sohns A, Holtta E . 2000 Cancer Res. 60: 5244–5253

  • Rosenberg CL, Kim HG, Shows TB, Kronenbergs HM, Arnold A . 1991 Oncogene 6: 449–453

  • Rosenberg CL, Wong E, Petty EM, Bale AE, Tsujimoto Y, Harris NL, Arnold A . 1991 Proc. Natl. Acad. Sci. USA 88: 9638–9642

  • Said TK, Luo L, Medina D . 1995 Carcinogenesis 16: 2507–2513

  • Said TK, Medina D . 1995 Carcinogenesis 16: 823–830

  • Said TK, Medina D . 1998 Mol. Carcinog. 22: 128–143

  • Scovassi AI, Stivala LA, Rossi L, Bianchi L, Prosperi E . 1997 Exp. Cell. Res. 237: 127–134

  • Sherr CJ . 1994 Cell 79: 551–555

  • Siciniski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards J, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ, Weinberg RA . 1996 Nature 384: 470–474

  • Siciniski P, Weinberg RA . 1997 J. Mammary Gland Biol. Neoplasia 2: 335–342

  • Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P . 1987 Cell 49: 465–475

  • Weinberg RA . 1995 Cell 81: 323–330

  • Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC . 1991 Mol. Cell. Biol. 11: 4846–4853

  • Yosogawa Y, Takamo Y, Okayasu I, Kakita A . 1998 Pathol. Int. 48: 717–722

  • Yu Q, Geng Y, Sicinski P . 2001 Nature 411: 1017–1021

Download references

Acknowledgements

We acknowledge Dr Charles J Sherr at the Department of Tumor Cell Biology, St Jude Children's Research Hospital, Memphis, TN, USA for the cyclin D2 cDNA. This study was supported by NIH grant CA-11944.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thenaa K Said.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kong, G., Chua, S., Yijun, Y. et al. Functional analysis of cyclin D2 and p27Kip1 in cyclin D2 transgenic mouse mammary gland during development. Oncogene 21, 7214–7225 (2002). https://doi.org/10.1038/sj.onc.1205895

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205895

Keywords

This article is cited by

Search

Quick links